Investor Relations

Press Releases

Date Title and Summary View
Aug 16, 2017

Presentation Scheduled on Thursday, September 7th, 2017 at 8:00 AM PT

Aug 03, 2017
PRINCETON, N.J., Aug. 03, 2017 (GLOBE NEWSWIRE) -- Agile Therapeutics, Inc. (Nasdaq:AGRX), a forward-thinking women's healthcare company, today announced the pricing of its underwritten public offering of 5,333,334 shares of its common stock at a public offering price of $3.75 per share.
Aug 02, 2017
PRINCETON, N.J., Aug. 02, 2017 (GLOBE NEWSWIRE) -- Agile Therapeutics, Inc. (Nasdaq:AGRX), a forward-thinking women's healthcare company, today announced that it intends to offer and sell shares of its common stock, subject to market and other conditions, in an underwritten public offering.
Jul 28, 2017
Cash Expected to Fund Operations into Q2 2018 FDA Assigns Prescription Drug User Fee Act (PDUFA)  Goal Date of December 26, 2017 PRINCETON, N.J., July 28, 2017 (GLOBE NEWSWIRE) -- Agile Therapeutics, Inc. (Nasdaq:AGRX), a women's healthcare company today reported financial results for the three and
Jul 27, 2017

FDA Assigns Prescription Drug User Fee Act (PDUFA) Goal Date of December 26, 2017

Jun 27, 2017
PRINCETON, N.J., June 27, 2017 (GLOBE NEWSWIRE) -- Agile Therapeutics, Inc., (NASDAQ:AGRX), a women's healthcare company, today announced it has resubmitted to the U.S. Food and Drug Administration (FDA) the NDA for its lead product candidate, Twirla ® , an investigational low-dose combined
May 08, 2017

Cash Expected to Fund Operations into Q2 2018

May 06, 2017

Newly Reported Bleeding Profile Shows Reduction in Unscheduled Bleeding/Spotting Days

May 03, 2017
PRINCETON, N.J., May 03, 2017 (GLOBE NEWSWIRE) -- Agile Therapeutics, Inc., (NASDAQ:AGRX), a women's healthcare company today announced that data from its Phase 3 SECURE study will be presented at the interactive ePoster session during the 2017 Annual Clinical and Scientific Meeting of the American
Apr 27, 2017
PRINCETON, N.J., April 27, 2017 (GLOBE NEWSWIRE) -- Agile Therapeutics, Inc. (NASDAQ:AGRX), a women's healthcare company announced today that a presentation entitled " An Update on Hormonal Contraception and The Changing U.S. Population " will be presented by Co-Principal Investigator of the SECURE